摘要
目的前瞻性观察前列地尔联合羟苯磺酸钙治疗心肾综合征的疗效和安全性。方法将78例心肾综合征患者随机分入治疗组和对照组,对照组采用慢性心力衰竭常规治疗方案,治疗组在此基础上静脉滴注前列地尔脂微球载体制剂及口服羟苯磺酸钙胶囊。检测两组患者治疗前后6min步行试验的步行距离(6MWD)、左心室射血分数(LVEF)、脑利钠肽(BNP)、肌酐清除率(CCR)及尿微量白蛋白/肌酐比值(ACR),并记录不良反应发生情况。结果治疗组和对照组治疗后的6MWD、LVEF、BNP、CCR和ACR均较同组治疗前显著改善(P值均<0.01),治疗组治疗前后各项指标的差值均显著大于对照组(P值均<0.01)。两组间不良反应发生率的差异无统计学意义(P>0.05)。结论前列地尔联合羟苯磺酸钙治疗心肾综合征具有良好的临床疗效和安全性。
Objective To prospectively evaluate the effect of alprostadil combined with calcium dobesilate on cardiorenal function in patients with cardiorenal syndrome. Methods Seventy-eight patients with cardiorenal syndrome were randomly divided into control group and treatment group. All the patients received conventional therapy of chronic heart failure. The patients in the treatment group were treated additionally by intravenous infusion of alprostadil lipo-preparation and oral use of calcium dobesilate capsule. Six-minute walking distance （6MWD）, left ventricuiar ejection fraction （LVEF）, brain natriuretic peptide （BNP）, creatinine clearance rate （CCR） and albumin/creatinine ratio （ACR） were recorded before and after treatment. Results There were significant differences in 6MWD, LVEF, BNP, CCR and ACR in all patients before and after treatment （all P~ 0.01）. There were also significant differences in the above mentioned parameters between the two groups （all P〈0.01）. Conclusion The function of heart and kidney can be greatly ameliorated by alprostadil and calcium dobesilate for patients with cardiorenal syndrome. （Shanghai Med J, 2013, 36： 236-238）
出处
《上海医学》
CAS
CSCD
北大核心
2013年第3期236-238,共3页
Shanghai Medical Journal
关键词
前列地尔
羟苯磺酸钙
心肾综合征
Alprostadil
Calcium dobesilate
Cardiorenal syndrome
